UBXN11 and hereditary disease: anakinra and rilonacept did not show positive signals at the SOC level, whereas canakinumab exhibited positive signals for infections and infestations (ROR: 2.58, 95% CI 2.49–2.67) and congenital, familial, and genetic disorders (ROR: 3.89, 95% CI 3.49–4.33).